Genenta Science (GNTA) Competitors $3.87 0.00 (-0.03%) As of 07/3/2025 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. TVGN, BTMD, INBX, DSGN, ESPR, NBTX, MDWD, CRDF, IMAB, and PRQRShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Semper Paratus Acquisition (TVGN), biote (BTMD), Inhibrx Biosciences (INBX), Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Its Competitors Semper Paratus Acquisition biote Inhibrx Biosciences Design Therapeutics Esperion Therapeutics Nanobiotix MediWound Cardiff Oncology I-Mab ProQR Therapeutics Semper Paratus Acquisition (NASDAQ:TVGN) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment. Which has stronger earnings & valuation, TVGN or GNTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSemper Paratus AcquisitionN/AN/A-$13.73MN/AN/AGenenta ScienceN/AN/A-$9.64MN/AN/A Which has more volatility & risk, TVGN or GNTA? Semper Paratus Acquisition has a beta of -0.73, suggesting that its stock price is 173% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Does the media prefer TVGN or GNTA? In the previous week, Semper Paratus Acquisition had 1 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Semper Paratus Acquisition and 2 mentions for Genenta Science. Semper Paratus Acquisition's average media sentiment score of 0.62 beat Genenta Science's score of 0.00 indicating that Semper Paratus Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Semper Paratus Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of TVGN or GNTA? 15.1% of Genenta Science shares are owned by institutional investors. 73.2% of Semper Paratus Acquisition shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is TVGN or GNTA more profitable? Company Net Margins Return on Equity Return on Assets Semper Paratus AcquisitionN/A N/A -934.56% Genenta Science N/A N/A N/A Do analysts rate TVGN or GNTA? Semper Paratus Acquisition presently has a consensus target price of $10.00, suggesting a potential upside of 703.21%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 546.16%. Given Semper Paratus Acquisition's higher probable upside, equities analysts plainly believe Semper Paratus Acquisition is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySemper Paratus Acquisition and Genenta Science tied by winning 4 of the 8 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.50M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E RatioN/A21.5627.6120.23Price / SalesN/A278.31417.23118.52Price / CashN/A42.7336.8958.10Price / Book5.237.518.035.67Net Income-$9.64M-$55.14M$3.18B$249.21M7 Day Performance24.81%4.61%2.93%3.28%1 Month Performance-10.02%4.72%3.75%5.55%1 Year Performance38.67%5.92%35.20%21.09% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science1.8724 of 5 stars$3.870.0%$25.00+546.2%N/A$69.50MN/A0.007TVGNSemper Paratus Acquisition3.9916 of 5 stars$1.16-3.3%$7.10+512.1%+81.5%$220.67MN/A0.003BTMDbiote3.1077 of 5 stars$4.01+1.3%$8.00+99.5%-43.1%$216.65M$197.19M6.57194News CoverageINBXInhibrx Biosciences1.217 of 5 stars$14.56-2.5%N/A+21.2%$216.12M$200K0.12166DSGNDesign Therapeutics0.3714 of 5 stars$3.90+4.3%$4.00+2.6%+18.2%$212.32MN/A-3.9440Positive NewsESPREsperion Therapeutics4.1378 of 5 stars$1.04-2.8%$7.00+573.1%-50.4%$212.07M$332.31M-1.30200NBTXNanobiotix1.6909 of 5 stars$4.45-0.5%$8.00+79.8%-7.1%$210.68M-$11.61M0.00100Positive NewsGap UpMDWDMediWound1.3216 of 5 stars$18.99-0.5%$31.80+67.5%+34.2%$206.32M$20.22M-9.0980CRDFCardiff Oncology1.7061 of 5 stars$3.16+1.9%$12.00+279.7%+62.5%$206.23M$680K-3.4320IMABI-Mab2.8968 of 5 stars$2.46-1.6%$5.50+123.6%+48.7%$204.15M$3.89M0.00380Gap UpPRQRProQR Therapeutics2.1302 of 5 stars$1.95+1.0%$8.00+310.3%+30.7%$203.06M$20.46M-5.57180News Coverage Related Companies and Tools Related Companies Semper Paratus Acquisition Competitors biote Competitors Inhibrx Biosciences Competitors Design Therapeutics Competitors Esperion Therapeutics Competitors Nanobiotix Competitors MediWound Competitors Cardiff Oncology Competitors I-Mab Competitors ProQR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
